Mental health and wellness company combining psychedelic research, technology, and medicine to optimize mental health care for patients and clinicians Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) has launched second stage of manufacturing synthetic Ibogaine which will be used in psychedelic clinical research.
During the second stage, the company will be assessing the quality of synthetic Ibogaine when manufactured at a large scale to establish the timing and cost for commercial-scale production.
Ibogaine is a psychoactive compound which can be found naturally in the roots of iboga tree which grows in Africa. Due to its psychoactive nature the plant has been traditionally used for spiritual and ritual purposes among the Bwiti tribe in Gabon.
Various studies as showed that ibogaine affects receptors known to have activity in pain, addiction, and neurodegenerative conditions. Some studies are currently underway to determine the potential of ibogaine to treat addictive disorders.
“We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of pharmaceutical grade product,” said the company’s CEO, Kelsey Ramsden.